A key focus of our research is the development of liposome based drug delivery systems (LDS). The LDS represents the most developed and promising form of nanovector, representing more than half of all ...

be used to carry anti-TB drugs. Many of the formulations presented are very similar to others that reach the market with regard to the size of the liposome and its constitution. However ...

12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024. This patent, titled "Delivery of ...

More than 4 million people in the U.S. have glaucoma, a group of eye diseases that can damage the optic nerve and lead to ...

liposome properties, such as size, surface charge and functionality, can be easily tuned. Polymeric nanocarriers can be categorized based on three drug-incorporation mechanisms. The first includes ...

Our liposomal drug delivery system offers a safer and more effective means of administering therapeutics like tacrolimus by targeting disease sites directly and minimizing the systemic side ...

Lipella Pharmaceuticals (LIPO) announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office ...

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today ...